Context Therapeutics Investor Presentation Deck

CLDN6 Prevalence in Cancer Cancer Testicular Ovarian Gastric NSCLC Malignant Rhabdoid (AT/RT and non-CNS) Breast Endometrial Glioma Bladder SCLC 17 Context Therapeutics Inc. - Sept. 2022 Prevalence (IHC, RNAseq) 95% 54-55% 13-55% 6.5-50% 29-44% 2-41% 20-31% 21% 2-8% 2% Reference Reinhard 2020 Reinhard 2020, Wang 2013 CLDN6xCD3 Bispecific Antibody Program Gao 2013, Kohmoto 2020, Lin 2013 Micke 2014, Reinhard 2020, Soini 2022, Wang 2015 Antonelli 2011, Sullivan 2012 Jia 2019, Reinhard 2020, Yafang 2011 Kojima 2020, Reinhard 2020, Ushiku 2012 Antonelli 2011 Reinhard 2020, Ushiku 2012 Reinhard 2020

View entire presentation